Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

exela pharma sciences, llc - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - bloxiverz is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. bloxiverz is contraindicated in patients with: risk summary there are no adequate or well-controlled studies of bloxiverz in pregnant women. it is not known whether bloxiverz can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited. all pregnancies, regardless of drug exposure, have a background risk of 2 to 4% for major birth defects, and 15 to 20% for pregnancy loss. no adverse effects were noted in rats or rabbits treated with human equivalent doses of neostigmine methylsulfate doses up to 8.1 and 13 mcg/kg/day, respectively, during organogenesis (0.1 to 0.2 times the maximum recommended human dose of 5 mg/60 kg person/day based on body surface area comparisons). anticholinesterase drugs, including neostigmin

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

exela pharma sciences, llc - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - bloxiverz is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. bloxiverz is contraindicated in patients with: risk summary there are no adequate or well-controlled studies of bloxiverz in pregnant women. it is not known whether bloxiverz can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited. all pregnancies, regardless of drug exposure, have a background risk of 2 to 4% for major birth defects, and 15 to 20% for pregnancy loss. no adverse effects were noted in rats or rabbits treated with human equivalent doses of neostigmine methylsulfate doses up to 8.1 and 13 mcg/kg/day, respectively, during organogenesis (0.1 to 0.2 times the maximum recommended human dose of 5 mg/60 kg person/day based on body surface area comparisons). anticholinesterase drugs, including neostigmin

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

max health limited - glycopyrronium bromide 0.5 mg/ml; neostigmine metilsulfate 2.5 mg/ml - solution for injection - active: glycopyrronium bromide 0.5 mg/ml neostigmine metilsulfate 2.5 mg/ml excipient: citric acid citric acid monohydrate dibasic sodium phosphate dodecahydrate sodium hydroxide water for injection - reversal of residual non-depolarising (competitive) neuromuscular block.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - neostigmine methylsulfate -

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

cantrell drug company - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - neostigmine methylsulfate 1 mg in 1 ml

Կանադա - անգլերեն - Health Canada

marcan pharmaceuticals inc - neostigmine methylsulfate - solution - 0.5mg - neostigmine methylsulfate 0.5mg - parasympathomemetic (cholinergic) agents

Կանադա - անգլերեն - Health Canada

marcan pharmaceuticals inc - neostigmine methylsulfate - solution - 1mg - neostigmine methylsulfate 1mg - parasympathomemetic (cholinergic) agents

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - neostigmine methylsulfate, quantity: 500 microgram - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate; dibasic sodium phosphate dodecahydrate; water for injections - neostigmine is indicated for:,? reversal of the effects of non-depolarising neuromuscular blocking agents.,? prophylaxis and treatment of post-operative intestinal atony and urinary retention.,? treatment of myasthenia gravis during acute exacerbations, when the condition is severe or in neonates.

Մալթա - անգլերեն - Medicines Authority

health house pharma ltd t/as p&d pharmaceuticals ltd 38 woolmer way, bordon, hampshire, gu35 9q, united kingdom - neostigmine metilsulfate - injection - neostigmine metilsulfate 2.5 mg/ml - other nervous system drugs

Մալթա - անգլերեն - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - neostigmine metilsulfate - injection - neostigmine metilsulfate 2.5 mg/ml - other nervous system drugs